|
|
 |
|
Viewing report
|
|
|
|
Blockbuster Drugs: A 2005-2014 Forecast
Decision Resources, Inc., Dec 2005, Pages: 79
Blockbuster drugs--drugs with annual sales topping $1 billion--accounted for approximately 30% of the pharmaceutical industry's total sales in 2004. In the next several years, patent expiries on many blockbusters will fundamentally alter the sales outlook for leading pharmaceutical companies. What strategies will companies pursue to replace sales lost to generics competition? Pursuit of new blockbusters is one approach, though the shift taking place in the therapeutic areas ripe for blockbuster development means that some companies must adjust their core competencies.
In this report, we identify drugs that we believe will achieve blockbuster status during a 2005-2014 forecast period, presenting them by therapeutic area and describing each drug's mechanism of action, performance in clinical trials, strengths and weaknesses, and competitive opportunities and threats. We also point to other drugs that are contenders for blockbuster status.
Customers who bought this item also bought
SPECIAL REPORT: Blockbusters Then and Now - Trends for Billion-Dollar Drugs
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
DPP IV Inhibitors - Global Strategic Business Report
Diabetes Market Forecast to 2015
Emerging Pharmaceutical Blockbusters: 2010’s Billion-Dollar Babies
Emerging Blockbusters: 2009's Most Promising Drugs and the Future of the Blockbuster Model
Successes and Failures for Avastin (Bevacizumab) mean Mixed News for the Blockbuster Drug in the Oncology Therapeutics Market
Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials
The Billion-Dollar Question: Which Emerging Agents Have Blockbuster Potential
The Future of eClinical Trial Solutions – Market Forecasts to 2015, Competitive Benchmarking and Case Studies
|
|
|
|
